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Abstract
Myosins constitute a large superfamily of actin-dependent molecular motors. Phylogenetic analysis currently places
myosins into 15 classes. The conventional myosins which form filaments in muscle and non-muscle cells form class II. There
has been extensive characterization of these myosins and much is known about their function. With the exception of class I
and class V myosins, little is known about the structure, enzymatic properties, intracellular localization and physiology of
most unconventional myosin classes. This review will focus on myosins from class IV, VI, VII, VIII, X, XI, XII, XIII, XIV
and XV. In addition, the function of myosin II in non-muscle cells will also be discussed. ß 2000 Elsevier Science B.V. All
rights reserved.
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1. Introduction
Myosins constitute a large superfamily of proteins
that share a common domain which has been shown
to interact with actin, hydrolyze ATP and produce
movement in all cases examined to date (Fig. 1) [1,2].
However, only a few members of the superfamily
have been biochemically characterized and it is pos-
sible that some myosins may have lost one or more
of these features. Myosins are typically constructed
of three functional subdomains: (1) the motor do-
main which interacts with actin and binds ATP, (2)
the neck domain which binds light chains or calmod-
ulin, and (3) the tail domain which serves to anchor
and position the motor domain so that it can interact
with actin. The motor domains are relatively con-
served with the exception of several surface loops
and the amino-terminus. Light chains and calmodu-
lin bind to a helical sequence termed the IQ motif
found in the neck which has a consensus sequence of
IQXXXRGXXXR [3]. The number of IQ motifs
present in the necks of di¡erent myosins can vary
between zero and six. The tail domains are the
most diverse domains and vary widely in length
and in sequence. Functional motifs, such as SH3
domains, GAP domains, FERM domains, and pleck-
strin homology (PH) domains are sometimes found
in the tails of myosins (Fig. 2). In addition, the tails
of many myosins contain coiled-coil forming sequen-
ces which allow the molecules to dimerize and pro-
duce two-headed molecules.
Phylogenetic analysis, usually of the motor do-
main, groups myosins into 15 distinct classes,
although there are a number of outliers which do
not adequately align with any of the established
classes [1,2]. In addition, two of the de¢ned classes
(IV and XII) are currently comprised of only a single
member. Perhaps, in hindsight, they should also have
been considered outliers. The nomenclature assigns
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class number II to the large family of ¢lament form-
ing conventional myosins which were discovered over
60 years ago and are found in muscles and in the
cytoplasm of animal cells. Class I myosins were
next discovered and the subsequent classes were
numbered in order of the discovery of the founding
member of the class. While most family trees are
constructed by analysis of the motor domains, anal-
ysis of the whole molecule or of the tail domains
alone generally gives the same relationships [4].
The number of myosin genes present in mammals
is conservatively estimated at 25^30 from classes I,
II, III, V, VI, VII, IX, X and XV. The entire genome
of the budding yeast, Saccharomyces cerevisiae, is
now sequenced and contains only ¢ve myosin genes,
two of class I, one of class II and two of class V [5].
The slime mold, Dictyostelium discoideum, represents
a higher level of organismal complexity. It can exist
as a single amoeboid cell or undergo a complex de-
velopmental cycle to produce multicellular slugs and
fruiting bodies. While the genome of Dictyostelium
has not been fully sequenced, a large of number of
myosins have been identi¢ed by a combination of
methods. These include seven myosin I genes, a sin-
gle myosin II gene and four other genes that do not
stringently group with the existing classes [4]. One of
these groups weakly with myosin V or XI while an-
other groups weakly with myosin VII or X. The two
remaining genes do not classify well with any existing
class. The sequence of the Caenorhabditis elegans ge-
nome is mostly complete. To date, there are four
genes for muscle myosin II, two for non-muscle my-
osin II, two for myosin I, one for myosin V, two for
myosin VI, one for myosin VII, one for myosin IX
and one for myosin XII [6] (M. Titus, personal com-
munication). No class of myosin appears to be uni-
versally expressed in all phyla. For example, no my-
osin II class molecules have yet been found in plants,
and several myosins are, so far, found exclusively in
plants (VIII, XI and XIII). However, all eukaryotic
animal cells examined contain at least one myosin II
gene and, usually, multiple myosin I genes. In addi-
tion, myosin V genes are found widely, if not univer-
sally (particularly if the criteria for relatedness are
relaxed somewhat).
The features of myosins from class I, III, V and IX
are covered elsewhere in this special volume [7^9]
and this article will concentrate on the remaining
classes. In addition, it will review the structure of
the myosin motor domain as determined by crystal-
lography of several myosin II myosin fragments and
what the structure, combined with site-directed mu-
tagenesis, can tell us about the function of the mol-
ecule.
2. The myosin II motor domain and its use as a model
for other myosins
The myosin II class is also referred to as ‘conven-
tional’ myosins since this was the only class of my-
osin known for decades. Members of this class are
hexameric enzymes composed of two heavy chains
with a molecular weight of 171^244 kDa and two
pairs of light chains. The amino-terminal portion of
the heavy chains (collectively referred to as the
‘head’) contains the prototypical motor domain and
two IQ motifs in the neck. The carboxyl-terminal
half of the heavy chain consists of coiled-coil forming
sequence which homodimerizes to form the long rod
(or tail) which usually terminates in a short non-hel-
ical segment [10^12]. Myosin II molecules have a
two-headed structure, due to the dimerization of
the heavy chain in the tail. The tails of myosin self-
associate to form ¢laments both in vivo and in vitro
at low ionic strength. Such ¢laments complicate ki-
Fig. 1. Phylogenetic tree obtained from neighbor joining analysis of the myosin motor domain protein sequences as performed by
ClustalW. Branch lengths are drawn to scale in units of percent divergence. The tree is drawn unrooted. Bootstrap resampling (1000
trials) was used to judge the robustness of nodes, and results are indicated on the ¢gure as explained in the key. Abbreviations are:
Ac, Acanthamoeba castellani ; Acet, Acetabularia cliftonii ; At, Arabidopsis thaliana ; Ae, Aequipecten irradians ; Bt, Bos taurus ; Bm,
Brugia malayi ; Ce, C. elegans ; Cc, Coturjix coturnix ; Dd, D. discoideum ; Dm, D. melanogaster ; En, Emericella nidulans ; Eh, Entamoe-
ba histolytica ; Gg, Gallus gallus ; Hr, Halocynthia roretzi ; Hs, Homo sapiens ; Lp, L. polyphemus ; Ma, Mesocritus aureus ; Mm, Mus
musculus ; Ov, Onchocerca volvulus ; Oc, Oryctolagus cuniculus ; Pp, Physarum polycephalum ; Pf, P. falciparum ; Rc, Rana catesbeiana ;
Rt, Rattus norvegicus ; Sc, S. cerevisiae ; Sm, Schistosoma mansoni ; Sp, S. pombe ; Ss, Sus scrofa ;, Tt, Tetrahymena thermophilus ; Tg,
T. gondii ; Xl, Xenopus laevis.
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netic and biophysical characterization of myosin’s
enzymatic activity. This complication can be circum-
vented by the use of proteolytically produced frag-
ments which are soluble and enzymatically active.
Myosin II molecules can be proteolytically cleaved
into discrete functional domains. One site of cleavage
at the junction between the head and the tail produ-
ces a soluble fragment termed subfragment one (S1)
and the rod which remains a coiled-coil dimer and
retains the solubility properties of the parent mole-
cule. S1 binds to actin and nucleotides and contains
the two light chains. Another cleavage site of myosin
II occurs about 40 kDa into the rod structure and
produces two fragments, heavy meromyosin (HMM)
and light meromyosin (LMM). HMM, which is solu-
ble even at low ionic strength, contains the head
region and a portion of the coiled-coil forming se-
quence (termed subfragment 2 or S2) which dimer-
izes to produce a two-headed fragment. LMM re-
tains the solubility properties of the parent
Fig. 2. Schematic representation of the domain structure of myosin superfamily members. The length of the molecules including their
various structural motifs is drawn roughly proportional to the number of amino acids. In some cases, members of a particular class
may have isoforms with alternatively spliced regions that change the length of the isoform.
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molecule. Both S1 and HMM have been critical to
kinetic, biophysical and structural studies of the my-
osin molecule.
The three-dimensional structure of fragments of
several myosin II molecules has been solved. The
fragments used for crystallography were produced
by proteolysis or by expression of recombinant mol-
ecules. These include the S1 of chicken fast skeletal
muscle myosin [13], the S1 of scallop myosin [14], a
recombinant fragment of the smooth muscle myosin
Fig. 3. Three-dimensional structure of chicken fast skeletal muscle myosin S1. The color scheme is as in Rayment et al. [13]. This ¢g-
ure was made with MOLSCRIPT [172].
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Fig. 4. Missense mutations of myosin VII and XV that give rise to deafness in mouse and human mapped onto the crystal structure
of chicken fast skeletal muscle myosin II. Mutations found in humans and mice associated with deafness are mapped onto the three-
dimensional structure of chicken fast skeletal muscle myosin S1 [13]. The mutations in green are found in myosin XV while those in
red are from myosin VII. The mutations are given the sequence number from their parent myosin backbone with the sequence num-
ber for chicken skeletal muscle myosin in parentheses. More information can be found about these mutations in Friedman et al. [157].
Mutations found in myosin XV: (1) G1358S (233); (2) C1775Y (674). Mutations found in myosin VII: (3) G25R (44); (4) R212H/C
(245); (5) G214R (247); (6) R241P/S (241); (7) R244P (277); (8) R302H (335); (9) A397D (428); (10) E450Q (476); (11) R502P
(528); (12) P503L (529); (13) M599I (Loop 2); (14) L651P (690). The structural elements of the motor domain are colored: Switch I,
cyan; Switch II, orange; P-loop, dark blue.
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motor domain containing the essential light chain
(ELC) [15], a motor domain fragment of Dictyoste-
lium myosin [16]. In addition, many of these struc-
tures have been solved with one of several di¡erent
nucleotides or nucleotide analogs bound at the active
site.
The myosin motor domain is essentially built of
four subdomains connected by £exible linkers [14]
(Fig. 3). The amino-terminal subdomain forms an
SH3-like motif in myosin II class molecules [15].
This motif is not present in other myosin classes.
The amino-terminal subdomain is connected to the
upper 50 kDa subdomain which is, in turn, con-
nected to the lower 50 kDa subdomain. The name
(50 kDa) for these two subdomains is historical and
relates to the fact that there are two proteolytically
sensitive surface loops which connect them with the
rest of the myosin molecule which when cleaved gives
rise to a band on sodium dodecyl sulfate^polyacryl-
amide gels with a molecular weight of 50 kDa [17].
The upper and lower 50 kDa domains are separated
by a cleft which is lined with many conserved resi-
dues. This cleft closes slightly upon binding nucleo-
tides and may close more dramatically upon binding
actin [14]. These two domains comprise most of the
actin binding interface (see [1] for a review of the
evidence). Of interest to later discussions of the my-
osin superfamily is a loop that is found at the surface
of the upper 50 kDa domain (residues 403^416 in the
chicken skeletal muscle myosin sequence). This loop
is the site of the ¢rst myosin mutation shown to
cause a human disease, hypertrophic cardiomyo-
pathy (HCM), and is sometimes referred to as the
HCM loop [18]. The HCM loop is also the location
of a phosphorylatable serine (S) or threonine (T) in
certain amoeboid myosin I molecules. (For an exten-
sive sequence alignment of myosin motor domains,
see [1]). The enzymatic activities of these myosins are
dependent upon phosphorylation at this site (see [19]
for review). The myosin VI class molecules also have
a threonine at this residue [20,21]. Most other myosin
superfamily members have a constitutively negatively
charged amino acid, either an aspartic acid (D) or a
glutamic acid (E) residue, at this site. For this reason,
Bement and Mooseker [22] named this the TEDS
rule site after the one letter codes for the four amino
acids involved.
The nucleotide binding pocket is rather open and
does not substantially close upon binding of nucleo-
tide (see [23] for review). It is formed primarily from
seven L-strands linked by loops [13]. There are many
structural similarities between the nucleotide binding
pocket of myosin and those of kinesin, a microtu-
bule-dependent motor and of G-proteins. [24,25]. In
each case, there are three conserved sequence ele-
ments termed the P-loop, Switch I and Switch II
that are involved in nucleotide binding and sensing
of the hydrolysis state (ATP or ADP) of the nucleo-
tide.
The fourth subdomain of the motor domain is
termed the converter region. A long helix emerges
from the converter domain which serves as the bind-
ing site of both light chains. The ELC occupies the
binding site closest to the converter subdomain while
the regulatory light chain (RLC) occupies the second
site. The binding sites are highly speci¢c for their
respective light chains. The elongated nature of the
neck region has given rise to the suggestion that it
acts as a lever arm to amplify small changes in the
sequence of the motor domain into much larger dis-
placements of actin [14]. In favor of this hypothesis,
it was found that there is a correlation with speed of
in vitro motility and the length of the neck region
from myosin mutagenesis experiments in which bind-
ing sites for light chains were either added or sub-
tracted to vary the length of the neck of Dictyoste-
lium myosin [26]. In addition, £uorescent probes
attached to the RLC of skeletal muscle myosin in
skinned ¢bers show a change in angle upon activa-
tion of the muscle [27]. Structural evidence in favor
of the lever arm hypothesis comes from crystal forms
of a smooth muscle motor domain containing the
ELC and from the scallop muscle S1 with di¡erent
bound nucleotides at the active site [14,15]. A portion
of this movement may have been directly visualized
in three-dimensional reconstructions of electron mi-
crographs of actin-myosin complexes in the presence
and absence of ADP [28,29]. These studies have led
to a model for force transduction that supposes that
the amino-terminal subdomain and the upper and
lower 50 kDa domains remain relatively constrained
as to their orientation with actin and that most of the
motion is derived from a rigid body movement of the
neck. The pivot point or joint for this movement is in
the converter subdomain and the movement is con-
trolled by conformational changes in structural ele-
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ments that are in communication with Switch II of
the nucleotide binding pocket [14].
Alignment of myosin sequences shows two main
hypervariable regions that occur at proteolytically
sensitive regions of myosin. Interestingly, these re-
gions are also the site of alternative splicing in
some myosin molecules (see below). The positions
of these hypervariable regions correspond to two
portions of the motor domain which were not re-
solved in the crystal structure probably due to their
disordered, £exible nature (Fig. 3). The ¢rst of these,
termed loop 1, occurs about 25 kDa from the amino-
terminus and is located near the nucleotide binding
region. Loop 2 occurs about 75 kDa from the amino-
terminus and is located in an actin binding interface.
Interestingly, binding to actin protects this region
from proteolysis [17].
The similarity in the motor domains from these
phylogenetically diverse myosin II crystals is remark-
able. In fact, alignment of the sequences of these
myosins with those of other myosin classes strongly
suggests that the myosin II motor domain crystals
are a good template for analysis of all motor do-
mains [30]. The alignment reveals that there is a con-
served core domain that begins about 80 amino acids
from the amino-terminus of the myosin II class mol-
ecules and continues to just before the beginning of
the long light chain binding helix [31]. Several myo-
sin classes have little or no sequence amino-terminal
to the core, while others have large extensions (see
Fig. 2 and below). There may also be large exten-
sions at the positions of loop 1 or loop 2 compared
to myosin II class molecules. Myosin VI has a unique
insert of about 50 amino acids at the converter re-
gion which will be discussed later. Finally, the length
of the light chain binding helix varies considerably
among myosins having anywhere from none to seven
IQ motifs. In myosin II molecules, there is usually a
26 amino acid separation between the start of IQ
motifs, but in unconventional myosins, the separa-
tion can be between 23 and 26 residues [32]. For
example, in myosin V molecules, the six IQ motifs
are separated by an alternating pattern of 23 and
25 residues. Since the heavy chain target for
light chain binding is a helix, the relative contacts
between adjacent light chains could be very di¡erent
depending on the spacing [32]. This could a¡ect the
sti¡ness of the neck, the relative disposition of the
heads and possibly the regulation of unconventional
myosins.
3. Myosin II
The most unique characteristic of myosin II is the
ability to form ¢laments via the self-association of
the rod-like coiled-coil K-helical tail. Bipolar ¢la-
ments such as those found in sarcomeric muscles
are formed by a combination of antiparallel tail in-
teractions at the middle of the ¢lament followed by
parallel interactions along most of the ¢lament
length. These ¢laments have a central bare zone
which is not populated by motor domains and are
designed to pull actin ¢laments toward there center.
Smooth muscle myosins can form side polar ¢la-
ments which have no central bare zone [33]. These
¢laments may allow for the extreme shortening that
is seen in smooth muscle tissues. The region of the
rod necessary for ¢lament assembly has been local-
ized in several cases [34^36]. It is typically a short
segment near the carboxyl-terminal one third of the
tail. A point mutation at Arg-1889 of Dictyostelium
myosin is su⁄cient to disrupt ¢lament assembly by
inhibiting the nucleation step [36].
Myosin II molecules can be subclassi¢ed into dis-
tinct classes based on sequence analysis of the motor
domains (Fig. 1). The sarcomeric myosins from stri-
ated and cardiac muscle fall into one group, whereas
vertebrate smooth and non-muscle myosins fall into
another. A third group is comprised of the myosins
from lower eukaryotic species such as Acanthamoeba,
Dictyostelium and Physarum and the fourth is from
fungi. The fungal myosins are the most dissimilar.
The coiled-coil forming sequences in their tails are
interrupted by numerous proline residues (see [37]
for review). Since no fungal myosins have yet been
puri¢ed, it is not clear whether they form ¢laments.
One of the Schizosaccharomyces pombe myosins ap-
pears to bind an EF-hand family protein, Cdc4p.
This myosin has one well conserved consensus IQ
motif and one that is very degenerate. It is not clear
whether it would bind two light chains [38]. This
protein, while not stringently grouping with either
RLC, ELC or calmodulin, appears to be most similar
to ELC. Interestingly, Cdc4p can be phosphorylated
in vivo at serine 2 or 6 [39]. Mutation of these resi-
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dues to alanines or to aspartates did not a¡ect
growth or cytokinesis [39]. There are no direct ho-
mologs of the ELC and RLC in the S. cerevisiae
genome and, instead, a protein with 40% sequence
identity to S. pombe Cdc4p is present as the best
candidate for a light chain [40]. It interacts both
genetically and directly by gel overlay assay with
the heavy chain of one of the myosin I genes,
Myo2. It will be interesting to know if this is also
a light chain for the myosin II protein of this species.
The MgATPase activity of vertebrate sarcomeric
myosins is constitutively activated by actin. The reg-
ulation in these muscles is via the troponin-tropo-
myosin system [41]. In contrast, the MgATPase ac-
tivity of most other myosins is regulated in one of
three ways. The MgATPase activity of molluscan
muscle myosins is greatly activated by calcium bind-
ing to the ELC [42,43]. Vertebrate smooth muscle
and non-muscle myosins are regulated by phosphor-
ylation of the RLCs by a calcium-calmodulin-depen-
dent enzyme termed myosin light chain kinase (see
[44,45] for review). Interestingly, the muscle myosin
of Limulus polyphemus, the horseshoe crab, is also
regulated by light chain phosphorylation [46]. Verte-
brate sarcomeric myosins are also phosphorylated on
their RLCs, but the e¡ect is only modulatory to-
wards its enzymatic or mechanical properties [47].
However, the phosphorylation of vertebrate striated
muscle RLC does disrupt the packing order of the
myosin heads against the backbone of the thick ¢la-
ment [48]. The heavy chains of vertebrate smooth
muscle and non-muscle myosins are phosphorylated
by a variety of kinases. The consequences of these
phosphorylations are not well understood [49^51] ex-
cept for the case of non-muscle myosin IIB, where
phosphorylation of the fragments of the heavy chain
results in an inhibition of ¢lament assembly [52]. In
contrast, the MgATPase activity of myosins from
Acanthamoeba and Dictyostelium myosins is inhibited
by heavy chain phosphorylation. The site of phos-
phorylation di¡ers between the two myosins and
the mechanisms by which phosphorylation inhibits
the activity of these two myosins are somewhat dif-
ferent (see [19,53] for review). The RLC of Dictyo-
stelium is also phosphorylated [54].
Much of our knowledge of the in vivo function of
non-muscle myosin II comes from studies in three
genetic model systems, Dictyostelium discoideum, S.
cerevisiae and Drosophila melanogaster. The single
myosin II gene of Dictyostelium was ablated by ho-
mologous recombination [55]. Surprisingly, cells
lacking non-muscle myosin II are viable if grown
on a surface where they divide through a process
termed traction-mediated cyto¢ssion [55^57]. In sus-
pension or on a non-adhesive hydrophobic surface,
the myosin II null cells undergo karyokinesis, but not
cytokinesis and large multi-nucleated cells are
formed [55,58,59]. Under these conditions, the Dic-
tyostelium myosin II null cells round up at the start
of mitosis, but they do not elongate nor form a
cleavage furrow [60]. On an adhesive surface, how-
ever, the traction-mediated cyto¢ssion events of the
myosin null are coupled to mitosis [60,61]. The cells
round up, elongate, exhibit polar ru¥ing and form a
cleavage furrow which decreases in width to eventu-
ally produce two daughter cells. However, the rate of
cleavage furrow constriction is only about half that
of wild-type cells [60]. These ¢ndings led to the pro-
posal that cytokinesis is driven by two mechanisms
[60]. Cytokinesis A is a myosin-dependent restriction
of the cleavage furrow and is the only event occur-
ring in Dictyostelium cells when they are not grown
on an adhesive surface. Cytokinesis B, which occurs
only on adhesive surfaces, is myosin-independent and
may result from the traction forces generated by po-
lar pseudopods exerting forces on the surface. The
studies of cytokinesis in Dictyostelium myosin II null
cells prompted a reinvestigation of the spatial distri-
bution of myosin II in mitotic cells [62]. This re-
vealed that when grown on a surface, very little my-
osin II gets targeted to the cleavage furrow.
However, when Dictyostelium cells are £atten under
agar, as is often used for imaging, the mechanical
stress results in a major recruitment of myosin to
the cleavage furrow [62]. This study concludes that
myosin II is not essential for cytokinesis.
Dictyostelium myosin II null cells can migrate and
chemotact towards a cAMP gradient, albeit some-
what ine⁄ciently, but do not complete the normal
developmental cycle [55,63^65]. They are unable to
cap surface receptors or do so poorly [57,66] and
there is reduced cortical tension in null cells com-
pared to wild-type [57]. The myosin null cells can
also serve as a host for reintroduction of mutated
myosin II constructs which can be puri¢ed for in
vitro biochemical assays [67,68]. Alternatively, the
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mutated myosins can be assayed for their ability to
restore wild-type phenotypes in such cell behaviors as
cytokinesis, motility, chemotaxis and development
[69^71]. The ability to perform both in vitro bio-
chemical assays and in vivo studies of mutated my-
osins constitutes a very powerful combination.
One example of this approach is the study of the
regulation of Dictyostelium myosin’s activity. Dic-
tyostelium myosin is phosphorylated at several
closely spaced threonine residues near the ¢lament
assembly domain in the tail and on the RLC
[72,73]. Phosphorylation of the heavy chain sites in-
activates the myosin by decreasing the propensity to
form ¢laments in vitro [74]. The role of RLC phos-
phorylation is not so clear. One study showed that
RLC phosphorylation is essential for in vitro motility
[54], but subsequent studies showed that RLC phos-
phorylation is more modulatory, producing only
about a 4-fold increase in the actin-activated MgAT-
Pase activity [75^77]. To study the e¡ect of heavy
chain phosphorylation, a construct which deleted
34 kDa of sequence around the phosphorylation sites
in the tail was expressed. This construct restores
some cellular function such as growth in suspension,
development and capping of surface receptors, but
the cells have altered cytoskeletal dynamics [78]. Spe-
ci¢cally, myosin does not properly disassemble once
recruited to a speci¢c site. In vitro analysis revealed
that the mutant myosin forms stable ¢laments. Site-
directed mutagenesis of the phosphorylation sites to
alanines gives the overassembly defect [69]. Conver-
sion of the phosphorylatable threonines to aspartates
results in phenotypes very similar to those of null
cells. The mutated myosin shows lower incorporation
into Triton insoluble cytoskeletons and appears to be
incapable of driving any contractile event within the
cell. Biochemical analysis of ¢lament assembly dem-
onstrates that the alanine mutants form stable ¢la-
ments whereas the aspartate mutants do not [69]. A
subsequent experiment used GFP-tagged myosins
bearing the alanine and aspartate mutations. Imag-
ing of living cells demonstrated that the amount of
aspartate mutant myosin that enters the cleavage fur-
row is drastically reduced, whereas the amount of the
alanine mutant myosin is much greater than wild-
type GFP-labeled myosin [79]. Thus, it appears that
as long as myosin can form ¢laments, it can carry
out cellular functions, but inhibition of ¢lament as-
sembly leads to a loss of myosin function and inabil-
ity to rescue the null phenotype. The major problem
with mutants that cannot be phosphorylated is excess
assembly in the recruited areas.
An RLC null line was created in Dictyostelium
which largely phenocopies the heavy chain mutants.
However, the interpretation of this experiment is
clouded by indications that the RLC-de¢cient myo-
sin aggregates in the cells [80]. In vitro studies with
chicken fast skeletal muscle myosin show that myo-
sin aggregates if the RLC is not present and that
myosin missing the RLC does not support in vitro
motility of actin ¢laments even though the actin-ac-
tivated MgATPase activity is not greatly impaired
[81]. Another approach used site-directed mutagene-
sis of the phosphorylation sites of RLC expressed in
the RLC null background. Replacement of the phos-
phorylatable serine on the RLC with an alanine fully
rescues the RLC null phenotype [77]. In vitro studies
showed that the non-phosphorylatable RLC mutant
myosin had a reduced actin-activated MgATPase ac-
tivity that was similar to that of myosin with a de-
phosphorylated RLC [77]. A separate experiment de-
leted the heavy chain sequence that comprises the
binding site for RLC [76]. The mutant myosin func-
tions in vitro (albeit with somewhat altered enzy-
matic properties) and is capable of rescuing most
wild-type phenotypes in vivo. A more detailed study
expressed a GFP-tagged myosin lacking both light
chain binding sites. The time course of cleavage fur-
row constriction, of nuclear separation and of cell
edge advancement is similar in both wild-type and
mutant myosin cells [60]. In combination, these stud-
ies support an important regulatory role for myosin
heavy chain phosphorylation in Dictyostelium, but
suggest that RLC phosphorylation may not be so
important.
Similar ‘rescue’ experiments have been used to
study the recruitment of myosin to the cleavage fur-
row during cytokinesis. A major question is how
does myosin get to the cleavage furrow. Several mod-
els have been proposed to explain myosin’s well
orchestrated localization during mitosis: (1) cortical
£ow generated by contraction of the cortex brings
the myosin and actin to the cleavage furrow [82],
(2) a gradient of kinases or phosphatases creates a
corresponding gradient of active myosin ¢laments
leading to the cleavage furrow, and (3) a myosin
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binding protein targets myosin to the cleavage fur-
row. The kinase model is weakened by the above
described myosin heavy chain phosphorylation sites
mutagenesis experiments which show that myosin
mutants which cannot be phosphorylated still be-
come targeted to the cleavage furrow [69,76^79,83].
Several recent experiments demonstrate that myo-
sin’s contractile activity per se is not necessary for
targeting to the cleavage furrow. A myosin lacking
the motor domain accumulates in the cleavage fur-
row as does a myosin carrying a mutation in the
motor domain that inactivates its actin-activated
MgATPase and in vitro motility [84,85]. These ex-
periments eliminate a cortical £ow model requiring
myosin II activity [86], but do not rule out such a
model if other mechanisms such as unconventional
myosins generate the driving force for the £ow. The
myosin binding protein model has been indirectly
tested in the many truncation and deletion experi-
ments that have been performed. Since headless my-
osin targets to the cleavage furrow, the putative
binding site cannot be in the head [85]. Similarly,
many of the tail deletions either rescue cytokinesis
in suspension or localize in the cleavage furrow
[78,84,87]. A recent study speci¢cally addressed this
question with a series of tail deletions as well as the
production of chimeric myosins containing the Dic-
tyostelium motor domain and tails from chicken skel-
etal muscle myosin [84]. All these constructs localize
to cleavage furrow and partially or completely rescue
cytokinesis in suspension. Thus, a putative myosin
binding protein targeted to a speci¢c area on myosin
probably does not exist, but rather the ability to
form a normal ¢lamentous structure may be critical.
In this regard, it is interesting that Dictyostelium my-
osin mutations that do not form ¢laments do not
rescue cytokinesis [55,69,88].
The Dictyostelium model system has also been use-
ful in detecting mutations critical to myosin function
using mutagenesis screens. Many of the mutations lie
within the motor domain although some are in the
tail. One screen identi¢ed a number of mutations
that line the cleft separating the upper and lower
50 kDa domains [89]. Another phenotypic screen
has identi¢ed a series of conditional mutants with
very di¡erent molecular phenotypes, some of which
a¡ect the binding of ATP and others a¡ect the cou-
pling between ATP hydrolysis and movement of ac-
tin [89]. Several are in the actin binding interface [90]
while another is in the rod region where it greatly
disrupts ¢lament assembly by interfering with the
nucleation event independently of altering phosphor-
ylation of the heavy chain [88].
The role of the single S. cerevisiae myosin II in
mitosis has been explored by ablation experiments
which show cytokinesis defects, although the exact
phenotype of the mutant was controversial [91,92].
After the ¢rst study which showed a cytokinesis de-
fect, a later study showed that the major defects in
the myosin II null cells were in chitin deposition to
the septum of the cell wall between the mother and
bud. Two recent studies revisited cytokinesis in yeast
using GFP-tagged myosin II expressed in the null
background. Myosin localizes in a contractile ring
at the site of the mother-bud junction and the diam-
eter of the ring decreases with time until only a spot
of myosin £uorescence is observed [93,94]. There are
two myosin heavy chain genes, Myo2 and Myp2, in
S. pombe [95,96]. Deletion of Myo2p is lethal due to
an apparent cytokinesis defect [95]. Deletion of
Myp2p is not lethal, but does show cytokinesis de-
fects under conditions of limiting nutrients [96]. GFP
derivatives of both of these myosins localize to the
contractile ring [95^97].
Drosophila has a single non-muscle myosin II
heavy chain gene that can be alternatively spliced
at the amino-terminus and at loop 1 [98,99]. It is
the product of the zipper locus which is embryonic
lethal due to a failure to complete dorsal closure
[100]. The Drosophila non-muscle RLC and ELC
genes have also been cloned [101,102]. The RLC
gene is the locus of the spaghetti squash (sqh) gene
which is embryonic lethal due to extensive failure to
complete cytokinesis [101]. The analysis of both the
zipper and sqh mutation is complicated by the con-
tribution of maternal protein which is su⁄cient to
allow the embryos to proceed through certain devel-
opmental events [100,101]. In order to study the role
of non-muscle myosin II in later development, an
RLC transgene with a heat shock promoter in the
sqh background was created [103]. Flies will develop
into normal adults provided they are heat-shocked
periodically to provide the RLC needed for function-
al myosin II activity. Heat shock can be withheld at
di¡erent developmental stages to determine the re-
quirement of myosin in various processes [103]. An-
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other study used a genetic trick in which RLC null
germ line cystoblast ovarian cells could be created
within an otherwise RLC wild-type £y [104]. These
two developmental studies, along with others that
analyzed mutant embryos or used antibody injection
techniques to disrupt myosin function, strongly sup-
port a role for non-muscle myosin in oogenesis. Mul-
tiple defects in this process can be detected including
defects in ring canal structure, in migration of follicle
cells and in dumping, the process late in oogenesis
whereby the nurse cells rapidly transfer their contents
to the oocyte [103,104]. Myosin II is required for
nuclear migration, cellularization, dorsal closure,
imaginal disc formation and cell sheet movement
[100,103,105]. The Drosophila RLC contains two
phosphorylation sites for myosin light chain kinase.
Mutation of these sites to alanine in germline cysto-
blasts does not rescue oogenesis, but conversion of
the primary site to glutamate allows for successful
completion of oogenesis, supporting a regulatory
role for RLC phosphorylation in this myosin [104].
There are two non-muscle myosin II genes in C.
elegans. One of these, nmy-2, is important in estab-
lishing embryonic polarity [106]. Injection of nmy-2
antisense RNA into the ovaries of adult worms
causes embryonic partitioning defects and is associ-
ated with mislocalization of PAR proteins which are
a family of proteins required for early asymmetrical
divisions. The PAR-1 protein, a putative Ser/Thr
protein kinase, immunoprecipitates with the tail of
NMY-2 from whole worm extracts. Antisense injec-
tion that targets the nmy-1 gene expression does not
give an embryonic lethal phenotype [106].
Vertebrates have two non-muscle myosin heavy
chain genes, termed non-muscle myosin IIA and
IIB [107]. Most cells express relatively equal amounts
of both of these myosins, with a few exceptions such
as platelets and chicken intestinal epithelial cells
which have only non-muscle myosin IIA and neuro-
nal tissues which express predominantly non-muscle
myosin IIB [108,109]. In tissue culture cell models,
RBL2H3 cells express only IIA whereas Cos cells
express only IIB (Dr. Robert Adelstein, personal
communication). Myosin IIA has a higher actin-ac-
tivated MgATPase activity and moves actin faster in
vitro than does myosin IIB [110]. The non-muscle
myosin IIB gene contains exons which are alterna-
tively spliced in neuronal tissue [111,112]. The alter-
native splicing introduces longer sequences at loop 1
or loop 2 or both. The signi¢cance of this splicing is
unknown as the spliced and unspliced loop 1 iso-
forms have relatively similar enzymatic activities
[113]. The smooth muscle myosin gene is also alter-
natively spliced at loop 1 which introduces seven
more amino acids. In this case, the longer isoform
translocates actin about 2.5 times faster than the
shorter isoform in vitro [114].
Myosin IIA and IIB localization varies between
di¡erent cell types. In general, both isoforms are
found in stress ¢bers in stationary cells, but myosin
IIB is often also found in the cell cortex
[110,115,116]. In several polarized migrating cell
types, myosin IIB is found at the leading edge
[110,117,118]. The non-muscle myosin IIB gene has
been knocked-out in mice by homologous recombi-
nation [119]. Heterozygotes are fully functional, but
homozygotes die in utero or within a few hours of
birth as a result of profound developmental defects
in the heart and show hydrocephalus of the brain. It
is interesting that cardiomyocytes express only non-
muscle myosin IIB and not IIA [109,120,121]. The
heart shows atrial-septal defects which mirror tetral-
ogy of Fallot in humans. The fact that the mice get
this far along in development suggests that myosin
IIB is not essential for cytokinesis, although it is
found at the cleavage furrow in dividing cells.
Other higher eukaryotic model systems suggest
that non-muscle myosin II is important in generating
forces within cells. The closure of puncture wounds
in Xenopus oocytes involves an actomyosin-generated
purse string [122]. Interestingly, myosin arrives at the
site of the wound before actin. A similar multicellu-
lar purse string can be seen during dorsal [100]. My-
osin ¢laments were directly observed by electron mi-
croscopy in ¢sh epidermal keratocytes [123]. These
rapidly migrating cells develop broad leading lamel-
lipodia that contain a dense meshwork of mostly
unipolar actin ¢laments. Short bipolar myosin ¢la-
ments are observed in the lamellipodia with the high-
est density seen near the cell body border. The dy-
namics of this actomyosin network are not consistent
with a sarcomeric contraction model of keratocyte
motility, but rather with a dynamic network contrac-
tion model where the forces for motility are gener-
ated in the zone between the cell body and the la-
mellipodia [123].
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Recently, non-muscle and smooth muscle myosin
II has been shown to be phosphorylated by several
kinases in various signal transduction pathways. The
RLC of smooth muscle myosin is phosphorylated by
Rho kinase at the same site phosphorylated by my-
osin light chain kinase, which may provide for a
calcium-independent pathway for activation of
smooth muscle [124]. Rho kinase also phosphorylates
myosin phosphatase and inhibits its activity [125].
This would also have the e¡ect of increasing the level
of activation of smooth muscle. However, the overall
picture is not so clear. Another kinase in the Rho
pathway, P21-activated kinase, phosphorylates myo-
sin light chain kinase and decreases its activity which
would decrease the level of myosin activity [126].
Recently, non-muscle myosin II has been shown to
be phosphorylated on the heavy chain in PC12 cells
following stimulation of the Rac pathway [127]. If
the heavy chain phosphorylation destabilizes ¢la-
ments [52] and is thus inhibitory, this would provide
a mechanism for the Rac opposition of the Rho
pathway.
4. Myosin IV
Myosin IV has thus far only been found in Acan-
thamoeba [128]. It links very loosely with myosin I
class molecules and was ¢rst termed HMW myosin I
(high molecular weight). The conserved motor do-
main is followed by a single IQ motif and a tail
lacking any coiled-coil forming sequence. There is a
MyTH4 domain in the tail which has homology to
similar domains in the tails of myosin VII and XV. A
preliminary study showed that it binds to actin, hy-
drolyzes ATP and moves actin ¢laments in vitro
[129].
5. Myosin VI
Myosin VI is a two-headed myosin with a single
IQ domain [20,21]. Its tail has a short segment pre-
dicted to form a coiled-coil, but is otherwise unre-
markable. The motor domain is unique in two re-
gions. There is a 25 amino acid insertion, which by
comparison with myosin II crystal structures should
be present in a loop at the surface of the upper 50
kDa domain, and another insertion of about 50 ami-
no acids just before the IQ motif. Similar to the low-
er eukaryotic myosin I molecules, all myosin VI mol-
ecules have a threonine at the TEDS rule site (amino
acid 406 of the mouse sequence). The motor domain
of myosin VI is phosphorylated in ¢broblasts and
p21-activated kinase phosphorylates the protein in
vitro [130]. While myosin VI has not yet been puri-
¢ed from tissue, a fragment corresponding to the
motor domain and the IQ motif has been expressed
in Sf9 cells via recombinant baculovirus infection
[131]. Interestingly, the myosin VI fragment translo-
cates actin ¢laments in the opposite direction than
that shown for other myosins. This is a result of the
50 amino acid insertion which probably alters the
converter subdomain. Cryo-electron microscopic
three-dimensional reconstructions of decorated acto-
myosin VI complexes show that the light chain bind-
ing region projects to the pointed end of the actin
¢lament [131]. Myosin VI is the only myosin to have
this particular insert at the converter region and,
thus, may be the only pointed end motor.
Myosin VI has been identi¢ed in pigs [21], mice
[132], chickens [130,134], humans [133], Drosophila
[20] and in C. elegans [6]. The Drosophila myosin
VI gene is found at locus 95F [20]. The protein is
associated with particles in syncititial blastoderms
which undergo cell cycle-dependent movements in
which transient membrane furrows are produced be-
tween adjacent mitotic spindles [135]. Microinjection
experiments with antibodies show that myosin VI is
essential to early development [136]. The injected em-
bryos show aberrant nuclear position and morphol-
ogy. In addition, the normal rearrangement of the
actin cytoskeleton during mitotic cycles is disrupted.
Myosin VI may be required to produce normal actin-
based transient membrane septa found in embryos.
Drosophila myosin VI is also involved in transport of
particles from nurse cells into oocytes during oogen-
esis [137].
In mice, myosin VI is encoded by the Snell’s walt-
zer deafness gene [132]. The mutant mice are congen-
itally deaf and exhibit waltzing and circling behavior
[138]. There are two alleles of the Snell’s waltzer lo-
cus. One, termed (sv), is a result of a splice site dele-
tion, which leads to a skipped exon and a frameshift
in the coding region. This results in premature ter-
mination of the protein around the single IQ motif
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[132] and e¡ectively creates a null mutation as no
protein is detected in any tissues by Western blotting.
The mutant mice show a progressive loss of cochlea
hair cells which begins at birth. By 6 weeks, very few
hair cells remain [66]. In addition, the membranes of
adjacent stereocilia fuse to form giant stereocilia
[139].
Myosin VI is found at several locations in the hair
cells of the ear. It has a prominent localization at the
cuticular plate at the base of the stereocilia which
serves to anchor the stereocilia to the soma [140].
It is particularly enriched in the pericuticular
necklace region between the circumferential actin
band and the cuticular plate. In addition, it is found
di¡usely in the cell body of hair cells. In frog inner
ear hair cells, it is also present at low levels in the
stereocilia. Hasson et al. [140] have proposed that
myosin VI may be responsible for the anchoring of
the stereocilia rootlets. In this regards, it is interest-
ing that myosin VI is also found in the terminal web
of polarized intestinal epithelial cells which also have
actin-rich microvilli where it may serve a similar
function [21,141].
Myosin VI is also expressed in most other tissues
and cell types [21]. It is localized to the Golgi com-
plex and to the leading edge of ¢broblasts suggesting
that it plays a role in membrane tra⁄cking [130].
However, the sv mutant Snell’s waltzer mice show
no obvious phenotypes, besides those described
above, which suggests that the membrane tra⁄cking
roles of this myosin are either not essential or are
redundant with other myosins or with microtubule-
dependent motors. In this regard, it is interesting that
Drosophila myosin VI interacts with D-CLIP-190
(cytoplasmic linker protein-190) [142]. This protein
is an orthologue of human CLIP-170 which links
endocytotic vesicles to microtubules [143].
6. Myosin VII
Myosin VII has been found in mouse [144], pig
[145], human [146,147], Drosophila [148] and in C.
elegans [6]. Two myosin VII genes, termed VIIA
and VIIB, have been localized in mouse [146]. My-
osin VIIA has a conserved motor domain followed
by ¢ve IQ motifs. A short predicted coiled-coil motif
in the tail probably allows for dimerization to form a
two-headed structure. The tail region contains two
FERM domains (formerly termed talin homology
domains) which have been implicated in cytoskeletal
protein interactions in other systems, two MyTH4
domains and an SH3 domain. The function of the
MyTH4 domains is unknown, but similar domains
are also found in myosin IV and myosin XV.
Mutations in myosin VIIA genes are responsible
for hereditary deafness in both mouse and human
[144,149^152]. In humans, myosin VIIA mutations
are associated with Usher syndrome type 1B
(USH1B), an autosomal recessive disease with sen-
sorineural hearing loss and retinitis pigmentosa that
gives rise to gradual blindness. It is the most com-
mon form of deafness-blindness. In addition, two
forms of non-syndromic deafness, DFNB2 and
DFNA11, are also caused by myosin VIIA muta-
tions [150,152]. Myosin VIIA is the locus of the shak-
er1 gene in mice [144]. Mice that are homozygous for
any of the seven shaker1 alleles exhibit deafness, hy-
peractivity and head tossing. Interestingly, the shak-
er1 mice do not experience retinitis pigmentosus
[144]. In this respect, the phenotype of these mice
more closely parallels that of the human non-syn-
dromic deafnesses which are not associated with ret-
initis pigmentosus. A possible reason for the lack of
associated blindness may be the short lifespan of
mice.
Myosin VIIA may be involved in stereocilia integ-
rity and in membrane tra⁄cking in the inner ear hair
cells. It is found in cross links of adjacent stereocilia
and in the cuticular plate [139,140]. The mutation
results in progressively disorganized stereocilia in
mice. The protein is also found in the pigmented
epithelium of the retina and in photoreceptor cells
where it is postulated to play a role in phagocytosis
and may function in the transport of opsin [153^156].
Nine missense mutations for human myosin VIIA
and two for mouse myosin VIIA have been described
that lie within the motor domain (see [157,158] for
review) (Fig. 4). The mutations can be mapped onto
the structure of chicken skeletal muscle myosin S1
[13]. Examination of the localization and nature of
the mutations reveal insights into possible molecular
abnormalities. Mutations at three of these sites,
R241P/S, R244P and A397D, are located on the
upper surface of the cleft that separates the upper
and lower domains at the tip of the myosin head
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while a fourth mutation, E450Q, lies at the bottom
surface of the same cleft and is at the start of the
Switch II region. Three of these amino acids, R241,
A397 and E450, are highly conserved among myosin
superfamily members. Several myosin VIIA muta-
tions lie in putative actin binding regions. The
M599I mutation lies within loop II at the tip end
of myosin which is thought to interact with the neg-
atively charged amino-terminus of actin. Recall that
this loop was not seen in the crystal structure, prob-
ably due to its £exible nature. In myosin II mole-
cules, this loop is longer and more highly charged
than it is in myosin VIIA, suggesting that the func-
tion of the loop may be somewhat di¡erent in the
latter myosin. Two other mutations, R502P and
P503L, lie on the outer surface of the lower domain
of myosin in regions that are thought to interact with
actin in myosin II. Mutations in two highly con-
served residues, R212H/C and G214R, lie at the start
of the Switch I segment. A ¢nal motor domain mu-
tant, G25R, lies at the amino-terminus in a region
with little conservation among myosin superfamily
members. Myosin VIIA has yet to be puri¢ed from
tissue or expressed in Sf9 cells so there is no infor-
mation on the enzymatic properties of the wild-type
protein, nor on the e¡ect of these mutations on ac-
tivity. Some of the mutations a¡ect the level of pro-
tein expression in mice which may also contribute to
the abnormality of the tissue [140].
7. The plant myosins: classes VIII, XI and XIII
Myosin VIII, ¢rst described in the plant Arabidop-
sis, has a predicted molecular weight of 131 000 Da
[159]. There is a 90 residue amino-terminal extension
of the motor domain, four IQ motifs and a short
segment of predicted coiled-coil forming sequence.
Another partially sequenced Arabidopsis myosin
VIII has been reported [160]. Virtually nothing is
known about its structure or function.
Myosin XI was also ¢rst identi¢ed in Arabidopsis
[161]. This myosin has many structural features sim-
ilar to myosin V, including six IQ motifs and a tail
with segments of coiled-coil interspersed with non-
helical segments.
Two myosin XIII genes have been reported,
termed MYO1 and MYO3 (accession numbers
O04146 and O04145). While their motor domains
are quite similar and they both have very short tails,
they di¡er in the number of IQ motifs found in the
neck region. MYO1 has 3^5 IQ motifs, whereas
MYO3 has 5^7.
Some alga species, such as Nitella and Chara,
show very rapid translocation of vesicles on oriented
actin cables [162]. Several groups have reported par-
tial puri¢cation of a myosin from Chara that trans-
locates actin ¢laments at rates up to 60 Wm/s [163^
165]. Interestingly, one of the groups rotary shad-
owed this myosin and found that its head length is
similar to that of conventional myosin II, suggesting
that none of the plant myosins cloned to date en-
codes this myosin [165].
8. Myosin X
Little is known about the function and localization
of myosin X. The protein was ¢rst identi¢ed in a
PCR screen from a frog inner ear library, but the
transcript does not appear to be very abundant in
this tissue and there is no known role for myosin
X in hearing [166]. The tail of myosin X has short
stretches of predicted coiled-coil forming sequence
and is dimeric. There is also a PH domain which is
also found in spectrin, dynamin, various GAPS and
kinases that interact with signal transduction path-
ways and the cytoskeleton. [167]. Three IQ motifs
follow the motor domain. Recently, a recombinant
fragment of myosin X corresponding to an HMM-
like fragment has been co-expressed with calmodulin
in Sf9 cells using baculovirus [168]. The MgATPase
activity is markedly activated by actin with a Vmax of
10 s31 and a KATPase of 5 WM at 37‡C. It moves actin
¢laments at a rate of 0.18 Wm/s in the in vitro mo-
tility assay. There is no activation of either activity
by calcium.
9. Myosin XII
This myosin was identi¢ed in C. elegans by the
genome project [6]. Its motor domain sequence is
even more divergent from the consensus than that
of myosin III. The heavy chain is very large
(300 000 kDa) with an amino-terminal extension of
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200 amino acids, two IQ domains and a very short
sequence predicted to form coiled-coil. However, un-
like most myosin classes, the putative coiled-coil
forming region is not juxtaposed to the last IQ, but
is situated in the carboxyl-terminal one third of the
tail. Whether myosin XII is a two-headed myosin
will await puri¢cation. There are two MyTH4 do-
mains in the tail.
10. Myosin XIV
Two members of the myosin XIV class were found
in the parasites Toxoplasma gondii and Plasmodium
falciparum [4]. Three transcripts were found in the
former which probably includes one case of an alter-
natively spliced gene. The myosins are the simplest in
composition containing a motor domain with no IQ
motifs and only a very short tail. It is not known
whether these myosins participate in the infectious
process.
11. Myosin XV
This recently discovered class of myosins was dis-
covered in a search for the human gene responsible
for DFNB3, a recessive, non-syndromic profound
congenital deafness [169]. The mouse ortholog is
the locus at the shaker2 gene in mice which is also
associated with deafness [170]. Myosin XV is the
largest myosin heavy chain found to date with its
longest transcript having a deduced size of 3530 ami-
no acids with a calculated molecular weight of
395 000 Da [171]. The gene encoding the protein
has 66 exons. The second exon of both the mouse
and human myosin XV encodes a proline-rich do-
main (of about 1200 amino acids) found at the ami-
no-terminus that has no obvious sequence homology
to other proteins. The tail of myosin XV does not
have any regions predicted to form coiled-coils.
However, there are similarities to the tail of myosin
VII in that there are two MyTH4 domains, two
FERM domains and an SH3 domain. Several of
the exons appear to be alternatively spliced, includ-
ing the large exon 2 and exon 8 which is 6 nucleo-
tides in length and encodes two amino acids that are
found in loop 1 by homology with chicken skeletal
muscle myosin [171]. Two mutations in the motor
domain of myosin XV have been described.
C1775Y is located close in space to the P-loop and
G1358S is located in the Switch I region [169].
The morphology of the shaker2 mice reveals some
insight into the function of myosin XV. Immuno-
£uorescent staining shows that myosin XV is present
in the cell body and stereocilia. In the shaker2 mice,
the stereocilia of the inner and outer hair cells are
only about one tenth of the normal length [170]. The
protein is found in the cell body and stereocilia of
both the inner and outer hair cells. The only other
tissue which shows a signi¢cant amount of message
for the protein is the pituitary [171].
12. Conclusions
Higher organisms clearly have a plethora of myo-
sin genes. Only a few myosins have as of yet been
studied in detail, but it is clear that they are involved
in many cellular processes where unique functions
are performed. One of the best studied cases to
date in the auditory system, where myosins from
class I, VI, VII and XV have been shown or postu-
lated to play critical roles [140]. In addition, myosin
V is certainly involved in neurotransmission in this
tissue. It is also becoming increasing clear that my-
osins provide an intimate link between signal trans-
duction pathways and the cytoskeleton. Myosins
may be a target for direct or indirect regulation of
their motor activity by signal transduction kinases or
these pathways may a¡ect the localization of myosin
or target association of myosin with other proteins
or factors within the cell.
Challenges remain to ¢nish the search for myosin
genes in humans and in model genetic systems, to
purify or express recombinant myosin molecules
that have yet to be studied in vitro, to localize the
tissue and intracellular distribution of myosins and
to screen for involvement in human disease or for
animal model systems with which to study myosin
function.
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